Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Insurance companies already are paying for it, and we haven't even factored in the global marketplace.
Oh My!! Is a party being planned for Vegas? It would be a great idea to do that and share info on future blockbusters like Aurinia.
Yep.......the untapped markets are just as exciting as what we're dealing with right now. It's all a matter of how they will be evaluated
It's interesting that GSK feigns no interest in AUPH. A-2 just blew the rest of Benlysta out of the water.
As of the end of June, Yahoo Finance reports that they are not one of the Top 10 institutional holders.... that collectively represents 30 million shares.
Maybe the CUSIP was reinstated solely so shareholders could get out at $1.00 through their broker-dealers, for the aggregate, to prove to their accountants that a sale was made.
The lack of a public reply, after a week, is sure to send some people to the exits. My belief is that A-2 is now a known quantity based on a "need to know" valuation of future expenditures for expanded NDAs. So, IMHO, we'll first get A-2 results and then find out who is grappling over control of AUPH.
There's an interesting side note to BMY. It is tendering its 11 1/2% stake in Acceleron to Merck, so its cash coffers will continue to grow.
Okay. Thanks. The rumored $42 and $44 price points are just that: rumors. I guess we should expect a lot of speculative banter from analysts going forward.
Ganz...can you elaborate?
.....and CITI commented that a merger with BMY made sense
Micham...Thanks for your career expertise and commentary. I think the company has done a great job, over the last four years, preventing leaks and keeping investors informed without hype. You offered an interesting premise that there is no pending acquisition via big pharma. Aurinia could, at least, have made a statement that it doesn't comment on rumors. What are your thoughts, now, after a couple of days have passed since your initial outreach to our group?
Perusing the articles about Aurinia, the question pops up as to who else might be interested. GSK, Astrazeneca, Takeda, Otsuka, and MRK also have been mentioned.
That recycled article remains bogus. Look at the timelines. We just found out less than a week ago from Bloomberg that Aurinia and Bristol were yakking. The article implies that the deal has been done for months (with no prior announcements) and was expected to close 9-30-21. I don't even have to call the author to ascertain the correct answer. Besides....$35 could wind up being waaaaay too cheap.
Think of the areas to be sorted: A Japanese distributor, European filings, product mfg. and trying to evaluate the potential markets yet to be tapped. A buyout would have been much simpler many months ago. Patience always has worked out here.
I agree, Ganz....yet Lilly failed with a Nephritis product while Glaxo's is vastly inferior. Who wants it the most? Who is the fourth company supposedly in the hunt?
Given where the markets are overall, I would expect analysts to be a bit cautious when they raise their price objectives. The boldest piece I saw was the weekend article by MF when it said, basically, that we could see a double from here. I don't think anyone would be upset somewhere in the middle with a 40+ top.
BMY is taking the risk that Aurora 2 is in good shape and that the revenue stream is progressing well. The Motley Fool's recent article suggests a buy-out price roughly twice what we have here.
Profit-taking from speculators is being met consistently with new buying from institutions as well as individuals. Give us a positive A-2 and a rising script count, and I think we could see 30 next month.
Reviewing the 2020 synopsis above and now perusing the candidacy for a treatment quality award, one might wonder if the current $24 price valuation, as "fully valued", is not really fully valued.
Well.....some of us are getting jumpy because the stock is up again and we're within a month of the next round of numbers being reported. Aurinia, historically, has done an good job of leak-free reporting. My own belief is that Aurora would have started showing efficacy slippage 12-18 months ago. That's just me with no scientific basis except for a little reported history. Competitors cannot ignore markets for Aurinia's products that haven't even been tapped at this point. Someone could buy this company now and acquire those future markets for the proverbial "song".
Yahoo!! There are a couple of their stocks than still can be shorted!
That so-called "article" looks totally bogus
I didn't think we would hit average volume numbers today until we started skirting $18.00. Then a huge splurge of buying came in and took it above average volume. The downside volume today was not a big deal. Healthcare stocks in general have had a tough week so far. Also remember that a couple of analysts referred to AUPH at 24 as a fully valued, fair priced security until the third quarter numbers arrive. We had over 850k shares bought in between 3:34 and 3:42 EDT.
Eli, BenK, and doc.....we happily rest our respective cases
Where Gensight is very close to having a marketable product (it's already being used for a few special situations), APTO is redoing a Phase 1 a/b test for acute leukemia conditions. The reason for the repeat performance is that the product, evidently, is safe and effective at more than one dosage level (a good spot to be in). So it's running a new test with increased dosage. I lost a 47 year old first cousin to acute leukemia in 1998, so this one really got my attention.
Hi Ganz. I checked out your MDRNF. I also have one with a tiny market cap, and both of them need to be able to trade a lot more freely. Yours is 63 million Canadian, and mine is 360 million Euros. I like the concept of MDRNF. There is room for more regional players in that market. Mine is a tiny French company located in Paris. It is called Gensight Biologics, GSGTF, and it has a pretty good hold on a few blindness issues. Terribly thinly traded, however.
The device worked, it was peer reviewed, and it was carried by two Canadian wholesalers.
....and the product or service to be offered is............
Do we have a guesstimate on potential market share and revenues based on Professor Galt's revelations? Potential suitors would know these stats and could try to take the company out early in an attempt to acquire those new markets for free.
The true value of MZEI and/or MZEIQ is ZERO only because the debts were unloaded during the Chapter 7....or the company would be worth less than ZERO. Sometime, hopefully soon, regulations will put this stock on the shelf forever....no trading....and still worth ZERO
So....on a negative quadruple witch.....with the NYSE Composite advances/declines being, at least, net down 1000 issues, Aurinia gets back on its roll to the tune of 5 million shares and holds $21. Not bad
The guy still owns 176,000 shares. I would say today's action is quite bullish given the gain into the wind of a quarterly quadruple witching event.
Classic positive backing and filling on almost 4.5 million shares today. Quite impressive!!
When Aurinia trades 2 million shares in a first hour, normally, that signifies a solid move. Trading 2 million shares in the final hour, however, is a totally different ballgame. There is an upside panic starting to emerge.
The "backing and filling" have been much more exuberant than "normal". Given a 270 down day in the DOW, a month ago AUPH would have followed it straight down. It looks like the mad dash for accumulation has begun. We're going to be treated to the "Sales and Suitors Show".
AUPH has ample mutual fund and institutional ownership, dominated by Fidelity. It looks like Fidelity owns just under the magical 5% number at 4.79%
I'm glad you enjoyed it too, BR. It certainly cracked up all of my nurses.
I also managed to blurt out a couple of my best off-color barnyard animal jokes in the OR as they were putting me under.
Thanks, Ganz. I tried to turn a serious situation into as much of a comedy show as I could muster. I hope Moose will share it with his bride.....but only after she has been cleared to laugh.
I realize that, OB. I'm just trying to save you all future aggravation and heartache. Life is too short. Move in to something that actually has a cutting edge product or service to provide. There are tons of them out there.